MARKET

AKTX

AKTX

Akari
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.641
-0.049
-2.91%
Opening 11:04 07/23 EDT
OPEN
1.670
PREV CLOSE
1.690
HIGH
1.684
LOW
1.610
VOLUME
37.13K
TURNOVER
--
52 WEEK HIGH
4.210
52 WEEK LOW
1.420
MARKET CAP
65.06M
P/E (TTM)
-2.5243
1D
5D
1M
3M
1Y
5Y
Akari Therapeutics announces private placement
Akari Therapeutics ([[AKTX]] -1.2%) has entered into definitive securities purchase agreements with institutional investors, led by existing investors of the Co., including Dr. Ray Prudo, Chairman, to receive gross proceeds of ~$12M
Seekingalpha · 07/07 14:00
Akari Therapeutics Announces Private Placement At Purchasing Price Of $1.55/ADS
Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the
Benzinga · 07/07 13:16
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 07/07 12:13
Akari Therapeutics Enters Deals to Raise $12 Million in Equity Private Placement
MT Newswires · 07/07 11:18
Akari Therapeutics reports Q1 results
Akari Therapeutics (AKTX): Q1 GAAP EPS of $0.00.As of March 31, 2021, the Company had cash of approximately $6.7 million, compared to cash of approximately $14.1 million at December 31,
Seekingalpha · 06/29 20:29
BRIEF-Akari Therapeutics Says Company Had Cash Of About $6.7 Million, Compared To Cash Of About $14.1 Million At December 31, 2020
reuters.com · 06/29 20:11
Geriatric Medicines Market : In-Depth Industry Analysis on Size, Cost Structure and Prominent Key Players Analysis
Japan, Japan, Thu, 06 May 2021 07:31:51 / Comserve Inc. / -- The report analyze market size, share, growth, trends, segmentation, top key players,...
Comserve · 05/06 14:55
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 05/04 12:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKTX. Analyze the recent business situations of Akari through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKTX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 2.41M
% Owned: 6.08%
Shares Outstanding: 39.65M
TypeInstitutionsShares
Increased
3
53.23K
New
3
74.06K
Decreased
3
758
Sold Out
3
233.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
+0.31%
Key Executives
Chairman/Director
Ray Prudo
Chief Executive Officer
David Solomon
Chief Financial Officer
Torsten Hombeck
Chief Operating Officer/Director
Clive Richardson
Vice President
Nigel Hernandez
Director
David Byrne
Director
Peter Feldschreiber
Director
Michael Grissinger
Director
Robert Ward
Director
Donald Williams
Non-Executive Director
James Hill
Non-Executive Director
Stuart Ungar
No Data
About AKTX
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4, or LTB4. It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement.

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.